Natixis
- SEC CIK
- 0001274981
- Latest filing
- Aug 13, 2026
NBIX holding history
Neurocrine Biosciences Inc in every 13F filed by Natixis, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NBIX overviewAll 13F holders of NBIXFull Q2 2026 holdings
- Shares (Q2 2026)
- 1,061
- Value
- $178.8K
- % of portfolio
- <0.1%
- Quarters held
- 20
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,061 | $178.8K | <0.1% | −1,586−59.9% | Reduced | Holders |
| Q1 2026 | 2,647 | $348.7K | <0.1% | −1,257−32.2% | Reduced | Holders |
| Q4 2025 | 3,904 | $553.7K | <0.1% | −1,469−27.3% | Reduced | Holders |
| Q3 2025 | 5,373 | $754.3K | <0.1% | +3,091+135.5% | Added | Holders |
| Q2 2025 | 2,282 | $286.8K | <0.1% | +1,053+85.7% | Added | Holders |
| Q1 2025 | 1,229 | $137.5K | <0.1% | −256−17.2% | Reduced | Holders |
| Q4 2024 | 1,485 | $202.7K | <0.1% | +918+161.9% | Added | Holders |
| Q3 2024 | 567 | $65.3K | <0.1% | −572−50.2% | Reduced | Holders |
| Q2 2024 | 1,139 | $156.8K | <0.1% | −442−28.0% | Reduced | Holders |
| Q1 2024 | 1,581 | $218.1K | <0.1% | −323−17.0% | Reduced | Holders |
| Q4 2023 | 1,904 | $250.9K | <0.1% | −578−23.3% | Reduced | Holders |
| Q3 2023 | 2,482 | $279.2K | <0.1% | −19,944−88.9% | Reduced | Holders |
| Q2 2023 | 22,426 | $2.11M | <0.1% | +6,001+36.5% | Added | Holders |
| Q1 2023 | 16,425 | $1.66M | <0.1% | −28,224−63.2% | Reduced | Holders |
| Q4 2022 | 44,649 | $5.33M | <0.1% | +44,649 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −2,122−100.0% | Sold out | Holders |
| Q2 2022 | 2,122 | $208.0K | <0.1% | −1,129−34.7% | Reduced | Holders |
| Q1 2022 | 3,251 | $305.0K | <0.1% | −543−14.3% | Reduced | Holders |
| Q4 2021 | 3,794 | $323.0K | <0.1% | −400−9.5% | Reduced | Holders |
| Q3 2021 | 4,194 | $402.0K | <0.1% | −3,230−43.5% | Reduced | Holders |
| Q2 2021 | 7,424 | $723.0K | <0.1% | +7,424 | New | Holders |